Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001493152-18-008582
Filing Date
2018-06-13
Accepted
2018-06-13 13:36:47
Documents
3
Effectiveness Date
2018-06-13

Document Format Files

Seq Description Document Type Size
1 defa14a.htm DEFA14A 28671
2 image_003.jpg GRAPHIC 118881
3 image_004.jpg GRAPHIC 98010
  Complete submission text file 0001493152-18-008582.txt   328813
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-51353 | Film No.: 18896291
SIC: 7389 Services-Business Services, NEC